Search results for "Delisting"
showing 4 items of 4 documents
Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting
2018
International audience; BACKGROUNDS & AIMS: Treating patients with decompensated cirrhosis with direct-acting antiviral (DAA) therapy while on the waiting list for liver transplantation results in substantial improvement of liver function allowing 1 in 4 patients to be removed from the waiting list or delisted, as reported in a previous study promoted by the European Liver and Intestine Transplant Association (ELITA). The aim of this study was to report on clinical outcomes of delisted patients, including mortality risk, hepatocellular carcinoma development and clinical decompensation requiring relisting. METHODS: One hundred and forty-two HCV-positive patients on the liver transplant waiti…
Il diritto all’oblio tra definizione sostanziale e rimedi di tutela. Riflessioni alla luce della giurisprudenza più re cente della Corte di Cassazion…
2023
The most recent judgements of the Court of Cassation and the Court of Justice of the European Union offer food for thought, to outline the different attitude of the balance between the protection of personal data and the right to information in the digital environment. These rulings in particular point out the reference to de-indexing as a useful remedy for the purpose of balancing opposing interests that does not disproportionately penalize the right to information, according to methods which, after some uncertainties, seem to highlight elements of convergence in the relative protection between the State level and the European level.
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study
2016
Background & Aims: All oral direct acting antivirals (DAA) have been shown to improve the liver function of patients with decompensated cirrhosis but it is presently unknown whether this clinical improvement may lead to the delisting of some patients. The aim of this study was to assess if and which patients can be first inactivated due to clinically improvement and subsequently delisted in a real life setting. Methods: 103 consecutive listed patients without hepatocellular carcinoma were treated with different DAA combinations in 11 European centres between February 2014 and February 2015. Results: The cumulative incidence of inactivated and delisted patients by competing risk analysis…